Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.
Zimmer Biomet has agreed to provide NeuroOne, a Minnesota developer of ultrathin electrode technology, with much-needed cash as the companies develop technologies for minimally invasive placement of a stereoelectroencephalography (sEEG) electrode on the brain.
Under a 2020 Exclusive Development and Distribution Agreement, Zimmer Biomet obtained exclusive global distribution rights to distribute NeuroOne’s Evo Cortical and Evo sEEG diagnostic electrodes in exchange for $2m...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
